Compare AREB & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AREB | ACXP |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 6.8M |
| IPO Year | N/A | 2021 |
| Metric | AREB | ACXP |
|---|---|---|
| Price | $1.05 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | ★ 930.4K | 79.9K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,014,691.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $3.17 |
| 52 Week High | $1,835.00 | $25.00 |
| Indicator | AREB | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 46.95 |
| Support Level | $0.90 | $3.98 |
| Resistance Level | $1.10 | $4.36 |
| Average True Range (ATR) | 0.14 | 0.39 |
| MACD | 0.09 | 0.11 |
| Stochastic Oscillator | 34.09 | 62.89 |
American Rebel Holdings Inc develops self-defense, safe storage, and patriotic product areas using a wholesale distribution network, utilizing personal appearances, musical venue performances, as well as e-commerce and television. It designs, manufactures, and markets concealed carry products. It offers products ranging in Backpacks, jackets, coats, and Others. The Company views its operations and manages its business as one operating segment engaged in patriotic goods, comprised of safes, soft goods, and beer.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.